| Dr Mitchell Howard Folbe, MD | |
|
115 E Long Lake Rd, Troy, MI 48085-5524 | |
| (248) 879-2500 | |
| (248) 879-2997 |
| Full Name | Dr Mitchell Howard Folbe |
|---|---|
| Gender | Male |
| Speciality | Medical Oncology |
| Experience | 32 Years |
| Location | 115 E Long Lake Rd, Troy, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255321683 | NPI | - | NPPES |
| 110F302150 | Other | BC | |
| 383355345 | Other | PPOM | |
| 900002413 | Other | PALMETTO GBA | |
| C7809 | Other | MCARE | |
| G55167 | Other | ALLIANCE HEALTH | |
| P94244 | Other | BCN MEDICAL ONE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 4301059575 (Michigan) | Primary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | MF059575 (Michigan) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital, Troy | Troy, MI | Hospital |
| Beaumont Hospital Royal Oak | Royal oak, MI | Hospital |
| Beaumont Hospital - Grosse Pointe | Grosse pointe, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Michigan Healthcare Professionals Pc | 0345413258 | 448 |
News Archive
Though "[c]holera vaccines are not a magic bullet and are not available in adequate numbers" to vaccinate everyone in Haiti, where at least 10 people die each day in an outbreak that began in October 2010, "there are compelling reasons to add vaccinations to the arsenal of public health weapons that has been deployed against cholera in Haiti," a Washington Post editorial states.
A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3-D) tumour model. As it replicates the conditions in the body, it is able to track the effectiveness and progress of drug therapy.
The new method achieves more predictable, stable drug levels in patients than the current method and could eventually allow doctors to more accurately adjust doses to accommodate individual differences in metabolism, thus increasing treatment effectiveness while avoiding side effects, said University of North Carolina at Chapel Hill researchers.
Scientists at Cold Spring Harbor Laboratory (CSHL) have created the first mouse model of pancreatic cancer that recreates two subtypes of the human disease.
Oncotarget recently published "Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer" which reported that the authors investigated whether Trop-2-expression and homologous recombination repair of SN-38-mediated double-strand DNA breaks play a role in the sensitivity of triple-negative breast cancer to SG.
› Verified 4 days ago
| Entity Name | Mclaren Oakland |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053463778 PECOS PAC ID: 0547173213 Enrollment ID: O20031111000770 |
News Archive
Though "[c]holera vaccines are not a magic bullet and are not available in adequate numbers" to vaccinate everyone in Haiti, where at least 10 people die each day in an outbreak that began in October 2010, "there are compelling reasons to add vaccinations to the arsenal of public health weapons that has been deployed against cholera in Haiti," a Washington Post editorial states.
A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3-D) tumour model. As it replicates the conditions in the body, it is able to track the effectiveness and progress of drug therapy.
The new method achieves more predictable, stable drug levels in patients than the current method and could eventually allow doctors to more accurately adjust doses to accommodate individual differences in metabolism, thus increasing treatment effectiveness while avoiding side effects, said University of North Carolina at Chapel Hill researchers.
Scientists at Cold Spring Harbor Laboratory (CSHL) have created the first mouse model of pancreatic cancer that recreates two subtypes of the human disease.
Oncotarget recently published "Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer" which reported that the authors investigated whether Trop-2-expression and homologous recombination repair of SN-38-mediated double-strand DNA breaks play a role in the sensitivity of triple-negative breast cancer to SG.
› Verified 4 days ago
| Entity Name | Bronson Battle Creek Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093119638 PECOS PAC ID: 0547173478 Enrollment ID: O20041103000774 |
News Archive
Though "[c]holera vaccines are not a magic bullet and are not available in adequate numbers" to vaccinate everyone in Haiti, where at least 10 people die each day in an outbreak that began in October 2010, "there are compelling reasons to add vaccinations to the arsenal of public health weapons that has been deployed against cholera in Haiti," a Washington Post editorial states.
A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3-D) tumour model. As it replicates the conditions in the body, it is able to track the effectiveness and progress of drug therapy.
The new method achieves more predictable, stable drug levels in patients than the current method and could eventually allow doctors to more accurately adjust doses to accommodate individual differences in metabolism, thus increasing treatment effectiveness while avoiding side effects, said University of North Carolina at Chapel Hill researchers.
Scientists at Cold Spring Harbor Laboratory (CSHL) have created the first mouse model of pancreatic cancer that recreates two subtypes of the human disease.
Oncotarget recently published "Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer" which reported that the authors investigated whether Trop-2-expression and homologous recombination repair of SN-38-mediated double-strand DNA breaks play a role in the sensitivity of triple-negative breast cancer to SG.
› Verified 4 days ago
| Entity Name | Michigan Healthcare Professionals Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295023547 PECOS PAC ID: 0345413258 Enrollment ID: O20111109000027 |
News Archive
Though "[c]holera vaccines are not a magic bullet and are not available in adequate numbers" to vaccinate everyone in Haiti, where at least 10 people die each day in an outbreak that began in October 2010, "there are compelling reasons to add vaccinations to the arsenal of public health weapons that has been deployed against cholera in Haiti," a Washington Post editorial states.
A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3-D) tumour model. As it replicates the conditions in the body, it is able to track the effectiveness and progress of drug therapy.
The new method achieves more predictable, stable drug levels in patients than the current method and could eventually allow doctors to more accurately adjust doses to accommodate individual differences in metabolism, thus increasing treatment effectiveness while avoiding side effects, said University of North Carolina at Chapel Hill researchers.
Scientists at Cold Spring Harbor Laboratory (CSHL) have created the first mouse model of pancreatic cancer that recreates two subtypes of the human disease.
Oncotarget recently published "Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer" which reported that the authors investigated whether Trop-2-expression and homologous recombination repair of SN-38-mediated double-strand DNA breaks play a role in the sensitivity of triple-negative breast cancer to SG.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mitchell Howard Folbe, MD 115 E Long Lake Rd, Troy, MI 48085-5524 Ph: (248) 879-2500 | Dr Mitchell Howard Folbe, MD 115 E Long Lake Rd, Troy, MI 48085-5524 Ph: (248) 879-2500 |
News Archive
Though "[c]holera vaccines are not a magic bullet and are not available in adequate numbers" to vaccinate everyone in Haiti, where at least 10 people die each day in an outbreak that began in October 2010, "there are compelling reasons to add vaccinations to the arsenal of public health weapons that has been deployed against cholera in Haiti," a Washington Post editorial states.
A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3-D) tumour model. As it replicates the conditions in the body, it is able to track the effectiveness and progress of drug therapy.
The new method achieves more predictable, stable drug levels in patients than the current method and could eventually allow doctors to more accurately adjust doses to accommodate individual differences in metabolism, thus increasing treatment effectiveness while avoiding side effects, said University of North Carolina at Chapel Hill researchers.
Scientists at Cold Spring Harbor Laboratory (CSHL) have created the first mouse model of pancreatic cancer that recreates two subtypes of the human disease.
Oncotarget recently published "Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer" which reported that the authors investigated whether Trop-2-expression and homologous recombination repair of SN-38-mediated double-strand DNA breaks play a role in the sensitivity of triple-negative breast cancer to SG.
› Verified 4 days ago
Dr. Mehmet E Donat, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4600 Investment Dr, Ste 380, Troy, MI 48098 Phone: 248-267-5025 Fax: 248-267-5026 | |
Dr. Timothy J Tinetti, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4600 Investment Dr, Ste 300, Troy, MI 48098 Phone: 248-267-5000 Fax: 248-267-5001 | |
Dr. Sundeep S Dhillon, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4600 Investment Dr, Ste 290, Troy, MI 48098 Phone: 248-267-5010 Fax: 248-267-5011 | |
Dr. Jared Seth Bortman, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 264 W Maple Rd, Suite 200, Troy, MI 48084 Phone: 248-273-9930 | |
Dr. Janet K Dubeck, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4600 Investment Dr, Ste 300, Troy, MI 48098 Phone: 248-267-5000 Fax: 248-267-5001 | |
Dr. Renato G Ramos, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1559 W Big Beaver Rd, Ste E, Troy, MI 48084 Phone: 248-649-0702 Fax: 248-649-9770 | |
Varinia Urday-gamalski, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 500 Kirts Blvd Ste 200, Troy, MI 48084 Phone: 800-759-7291 |